Exact Sciences Corporation (NASDAQ:EXAS) insider Graham Peter Lidgard sold 45,775 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $53.60, for a total transaction of $2,453,540.00. Following the sale, the insider now owns 272,819 shares in the company, valued at $14,623,098.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Graham Peter Lidgard also recently made the following trade(s):

  • On Monday, October 2nd, Graham Peter Lidgard sold 81,025 shares of Exact Sciences Corporation stock. The stock was sold at an average price of $47.16, for a total transaction of $3,821,139.00.
  • On Tuesday, September 5th, Graham Peter Lidgard sold 75,683 shares of Exact Sciences Corporation stock. The stock was sold at an average price of $40.81, for a total transaction of $3,088,623.23.
  • On Friday, September 1st, Graham Peter Lidgard sold 45,775 shares of Exact Sciences Corporation stock. The shares were sold at an average price of $41.49, for a total transaction of $1,899,204.75.

Exact Sciences Corporation (EXAS) traded up $3.70 during mid-day trading on Friday, reaching $56.71. The company had a trading volume of 1,500,141 shares, compared to its average volume of 1,835,029.

Exact Sciences Corporation (NASDAQ:EXAS) last released its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. During the same quarter in the previous year, the business posted ($0.36) earnings per share. The business’s revenue for the quarter was up 158.4% on a year-over-year basis. equities research analysts predict that Exact Sciences Corporation will post -1.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/03/exact-sciences-corporation-exas-insider-graham-peter-lidgard-sells-45775-shares.html.

A number of institutional investors have recently added to or reduced their stakes in EXAS. BlackRock Inc. grew its position in Exact Sciences Corporation by 45,816.0% in the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock valued at $160,718,000 after acquiring an additional 6,789,478 shares during the last quarter. Fred Alger Management Inc. bought a new position in Exact Sciences Corporation in the second quarter valued at about $84,177,000. Lord Abbett & CO. LLC grew its position in Exact Sciences Corporation by 59.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after acquiring an additional 875,527 shares during the last quarter. Victory Capital Management Inc. bought a new position in Exact Sciences Corporation in the second quarter valued at about $29,450,000. Finally, Vanguard Group Inc. grew its position in Exact Sciences Corporation by 8.0% in the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after acquiring an additional 700,051 shares during the last quarter. Hedge funds and other institutional investors own 85.12% of the company’s stock.

Several equities research analysts have issued reports on the company. Leerink Swann reaffirmed an “outperform” rating and set a $63.00 price target (up previously from $50.00) on shares of Exact Sciences Corporation in a report on Tuesday. Benchmark Co. reaffirmed a “buy” rating and set a $60.00 price target (up previously from $50.00) on shares of Exact Sciences Corporation in a report on Tuesday. Canaccord Genuity raised Exact Sciences Corporation to a “buy” rating and set a $60.00 price target for the company in a report on Tuesday. Craig Hallum raised their price target on Exact Sciences Corporation from $46.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Robert W. Baird raised their price target on Exact Sciences Corporation from $49.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Exact Sciences Corporation presently has a consensus rating of “Buy” and an average target price of $49.71.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.